



# Dr Muzamil Asif MBBS, MD, FRCR

---

## Present Appointment

**Head of Specialty, Clinical Oncology**  
**Lead for Stereotactic Radiotherapy for Oligometastatic Cancer**  
Imperial College Healthcare NHS trust (2022 - present)

**Consultant, Brachytherapy lead**  
Imperial College Healthcare NHS trust (2017 - present)

## Medico-Legal Experience

Experienced Consultant Clinical Oncologist, specialising in the treatment of **Gynaecological, Gastrointestinal and Haematological** malignancies. Treatment specialisms include **stereoactic radiotherapy** and **brachytherapy**.

Specialist reporting since 2021, on Breach of Duty, Causation, Tumour Doubling Time, Condition and Prognosis, and issues around Standards of Care. Accepts 20 – 30 reports per year for claimant and defendant.

## Previous Appointments

**Clinical Oncology Fellow**  
Imperial College Healthcare NHS Trust (04/2016 – 06/2017)


**Registrar**  
Sri Shankara Cancer Hospital (07/2014 – 11/2015)


**Senior Resident**  
Jipmer, India (04/2012 – 06/2014)

**Specialist Registrar, full-time**  
Jipmer, India (04/2009 - 04/2012)



[contact@cancerlegalexperts.co.uk](mailto:contact@cancerlegalexperts.co.uk)





### Research

Experienced clinical researcher with a sustained leadership role since 2017 as Chief Investigator for the MAHOGANY trial in the UK.

Served as Principal Investigator and Sub-Investigator on multiple commercial trials in Upper GI and gynaecological cancers.

Previous roles include Principal Investigator at JIPMER (India), and earlier research positions as a Research Assistant at the Brown Cancer Center (USA) and KIMS (India).

### Publications

Author of multiple peer-reviewed publications spanning early-phase clinical trials, haematological malignancies, and radiation oncology. Recent work (2024) focuses on prognostic scoring in early-phase cancer trials and long-term outcomes of stem cell transplantation in cutaneous T-cell lymphomas. Earlier publications include research on brachytherapy techniques in cervical and tongue cancers, radiotherapy-related DNA damage, and dosimetric optimisation in gynaecological oncology, demonstrating a consistent focus on clinical outcomes and radiotherapy innovation.

### References

Available upon request

